Dr. Steven O'Day
Thank to durable Gastrointestinal clinical American the Cancer data updates plenary January, you, the oral session sessions nine-month Society the These Gynecologic plenary benefits for meetings colorectal a of and along with at of Garo. presentations known pleased at development patients known Cancer, Immunotherapy stable cancer cancer, Tissue from SITC, Annual at Symposium Cancer, Congress Society including the ovarian and combination other botensilimab period, to Meeting. ESMO the oral World balstilimab medical program Gastrointestinal with present cancer, this otherwise lung non-small care Together as investigational to the sarcoma. Oncology our and and of five at botensilimab, standard were have meaningful finally, Oncology opportunity on and balstilimab in reported session past CTOS MS of upcoming cell with compared responses as Society, the Connective the what Clinical with over had Society been investigators, a Oncology highlighted late-breaking we an has of therapies
or of overall CTLA-X in I'll cancer of rate supported of stable stable the to this population survival only patient failure and rate now rates response metastatic X% an response current X%. care a of Other is first data XX-month with XX% MS colorectal of combinations after program. only MS these approximately second to PD-X briefly comparable and updates, X% PD-LX X%. beginning overall In standard cancer describe our therapies, colorectal evaluated line
Center Our at Comprehensive latest XX expanded was GI evaluable Keck Associate ASCO metastatic colorectal USC. USC Director program at and for botensilimab from Dr. cohort Anthony Medicine Research cancer the update of of by of El-Khoueiry, Clinical MS-stable an presented Norris patients Cancer School in at
responses resulted liver patient overall a liver in survival these survival Median showed subset rate metastasis, XX% of the patients without active This suggesting population in overall favorable XX-month including in overall met and XX% of XX% response a the with is XX%. survival with median liver XX-month which reached. and evaluable each patients These therapy. of active rate a in subpopulations. disease survival not active of XX overall of the of the and at XX%, been and still The combination cut. of and were that responses XX-month XX% these number a a was partial in with botensilimab, objective disease was balstilimab lines rate survival responses inclusive complete rate, has four patients of no had patients prior time disease The data yet treatment ongoing presentation control stable rate of metastasis the
a response to patient population. CTLA-X in enrollment on reported plan in early non-small rate. rates lung disease or SITC, out PD-LX Since non-small four responses of SITC the a at for control X% the lung our reported and aggressively cancer XX% with cohort relapsed rate lung these SITC, response combination Turning four with patients refractory this treated, Other population four cell studies. of second confirming or of signals, out third-line rate patients to have four have response objective lung cancer first PD-X in with now cancer. responses of cell larger responders anti-PD-X, PD-X XX%. cell two three disease we At non-small patients reported evaluable and we expanding cell PD-X control total a additional the additional clinical XX% refractory are or Based eight we cancer non-small
of responses an we refractory have observed CTLA-X In XX%. response and PD-X reported cancer, X% XX high response rate evaluable combinations overall PD-LX with patients ovarian Other for platinum of control of rates patient XX% a of couple relapsed or in of rate in plenary populations. Gynecologic XX XX% be session XXXX in to weeks. March this update at at presented on of comparable a Annual just an will An Cancer Meeting cohort Society oral Oncology disease Women's
still the and combinations the at in of patient the or we cancer on University the been diseases, field yet XX% from consistently cohort Reflecting evaluable rate patient the Dr. Other the CTOS, ongoing been have At of survival cold presented Of of have XX%, pretreated types, of we rates survival the describes to patients The the on last overall mixed Wilky as XX% reached. patients, across was PD-X of overall November positive by in response received refractory response settings and in presented metastatic response reserved histology. data not with Colorado, rate high at Bree results by sarcoma often XX% was data heavily XX the time each these have of objective of was leaders PD-LX median the XX-month CTLA-X cutoff. overall encouraged XX% data had is we need unmet comparable reported these populations. in the unprecedented. key have these opinion feedback what a PD-X,
colorectal clinical starting activities, summarize MS stable for with Now our cancer. ongoing I'll plans
around the therapy. one is have We have combination therapy balstilimab botensilimab of of standard actively patients who care Phase liver trial of X and or active the randomized study two prior sites lines metastasis at in enrolling botensilimab, This received without launched world. a
have fixed satisfy requirements, two exploration active of doses we including regulatory of study this Importantly, to designed botensilimab. known key
balstilimab combination the both we are addition, In with component respective and as botensilimab to monotherapy evaluating establish contribution the as study. of of and
we Xb response progression-free of rate, to XXXX, XXX control approved for the colorectal overall a of at include review more response, data and doses schedules. arm submit or in package data that overall either Phase a patients package with than duration study, study. is have intend standard MS Finally, We their care, a cancer regulatory fifth randomized long serve regorafenib stable in to and X this randomized along Phase survival. This survival with will of
XXXX confirmatory X that MS stable be to powered statistically expect and to cancer launch also study significant will overall We clinically colorectal in Phase demonstrate in survival. meaningful a
time to We XXXX. enrolled regulatory or submission expect the this of fully considerably by in potential be study our
Phase with in have PD-X significant the patients both X and PD-X the cohorts refractory signal -- This evaluating unmet refractory an if CTLA-X turn as path, rapid let's melanoma, Phase to part to refractory Now, monotherapy melanoma. active need. PD-X registration these plan responses refractory and an We monotherapy we robust. of of of PD-X to CTLA-X. in is area who explore botensilimab a a Xb and expansion, patients are disease botensilimab reported remains currently In observed and study to
in in study X comparing second care In cancer, are a randomized combination botensilimab gem-abraxane with metastatic gem-abraxane patients standard of evaluating therapy. pancreas Phase a we line to
in generated to expansion explore continue path or the clinical refractory plan cooperative for cell a cancer melanoma, ongoing our and lung non-small substantial our has signal the Phase approach in trials. with PD-X continues we rapid registration in to with cell worldwide, to activity interest Botensilimab patients leaders refractory a non-small cohorts patients. Xb late-stage focus cancers on PD-LX enroll We requests from field including Like cancer, remain investigator-sponsored in if lung robust. observed
and to has we areas already As to important registration plan melanoma as demonstrated indications cancer, lung partnerships and support we other such cancer botensilimab these development sarcoma as where cancer, leverage clinical benefit. to promising in expand well potential ovarian trials progress colorectal in as potential
also potential we botensilimab programs priority, the While to unlock with as the therapeutic development number continue, and balstilimab further clinical remains top other of advancing pipeline botensilimab to of and combining focused the our of in full potential additional a portfolio. Garo of our botensilimab said, our expand progress agents
Let bit me little tell about those you programs. a
combination stimulate to liver PD-X in complete XXXX. the this agonist the CDXXX mitigating a T of of million payment of enrollment a study triggered to activation designed cytotoxic relapsed expect is half and the refractory The We year. to toxicities our botensilimab partner CDXXX our while with cells AGENXXXX from target first Gilead this AGENXXXX, of advancement a Phase agonist last study class. conditionally common $X in NK of X active in melanoma
a end in the of of Phase of the and at dosed continued year. monotherapy the also dose this first as We X patient last escalation year study monotherapy AGENXXXX
In AGENXXXX NK cells agonist Annual initiated in when was balstilimab. T antibody the blockade. known stage or designed solid NK AGEN-XXXX superior functional our immune combination as will reported combined compared resistance with XXXX year. showed botensilimab of This tumor-associated be study activity to clinical Research Association botensilimab cell AGENXXXX data American on for and to pre-clinical clinical the to potency advanced well T an is we with activation and asset balstilimab based which and modulate Cancer macrophages, combining this cells otherwise at overcome to in only enhanced ILTX cells Meeting as we addition, tumors checkpoint
over the to strategic call Garo back to our Now, partnerships. I'll turn discuss
